Canine Cancer Screening Market Report 2025: IDEXX Laboratories, Zoetis, And Heska Corporation Lead This Rapidly Evolving Industry

(MENAFN- GlobeNewsWire - Nasdaq) The key market opportunities in canine oncology diagnostics lie in adopting advanced molecular biology and imaging technologies for early cancer detection. Collaborative innovations in reagents and imaging, next-gen sequencing, liquid biopsies, and AI are reshaping precision care. Tariff adjustments prompt supply chain diversification, while strategic partnerships and vertical integration enhance value delivery. Additionally, a keen focus on regional dynamics, tailored service models, and regulatory alignment drive adoption and sustainable growth globally.

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Canine Cancer Screening Market by Product Type, Technology, End User, Cancer Type, Sample Type and Region - Global Forecast 2025-2030" has been added to ResearchAndMarkets's offering.

Key Takeaways from This Report

• Rapid technological advances are revolutionizing early detection and personalized intervention strategies, fostering a competitive advantage.
• Tariff adjustments are reshaping procurement strategies, emphasizing the need for resilient supply chains and diverse supplier portfolios.
• Detailed market segmentation reveals critical insights into diverse demand patterns, enhancing strategic planning and market entry strategies.
• Regional growth dynamics highlight opportunities for global expansion and strategic investment based on regional infrastructure and policy landscapes.
• Collaboration and innovation within the competitive landscape are pivotal for sustaining growth, ensuring data-driven decision-making, and improving clinical outcomes.

In the rapidly evolving field of canine oncology diagnostics, new screening methodologies are dramatically improving early detection capabilities. These advancements are driven by cutting-edge molecular biology and imaging technologies, which allow practitioners to identify malignant conditions at more subtle stages.

This progression from traditional histopathological assessments to high-resolution sequencing and noninvasive imaging highlights the crucial need to integrate innovative technology with clinical expertise. By fostering collaboration among veterinary clinics, research institutes, and diagnostic labs, the sector is refining reagents and kits, advancing imaging instruments, and enhancing diagnostic protocols. Such developments promise to refine strategic planning and foster competitive advantage through improved diagnostic accuracy and patient outcomes.

Disruptive Technological Advancements in Canine Cancer Screening

New technologies and clinical demands are reshaping canine cancer screening. Next-generation sequencing has moved from the research realm to a key diagnostic tool, enabling high-throughput genomic profiling with unprecedented precision. Liquid biopsies and biomarker assays are transforming noninvasive screening into pathways for real-time tumor monitoring. Digital pathology and AI-driven image analysis further streamline diagnostics by automating lesion detection and accelerating results, aiding in strategic decision-making and opportunity identification.

Impact of 2025 U.S. Tariff Adjustments on Canine Cancer Screening

The inclusion of tariffs on critical inputs such as high-precision imaging instruments and specialized reagents has introduced significant cost pressures. These policy changes are prompting stakeholders to diversify supplier portfolios and explore domestic production partnerships to maintain financial sustainability and secure market entry strategies. In response, veterinary hospitals and laboratories are leveraging alternative procurement strategies such as volume-based agreements and reagent rental models to mitigate risks while preserving service quality.

Segmentation Dynamics in Canine Cancer Screening Market

This report provides a detailed segmentation analysis, highlighting product distinctions among imaging instruments, molecular analyzers, and sequencing platforms. On the technological front, matured biomarker assays coexist with advanced genetic testing modalities, enhancing diagnostic resolution and procedural efficiencies. The report further explores cancer type differentiation, end-user demands, and sample type variety, offering comprehensive insights into market dynamics that aid in strategic entry and competitive positioning.

Regional Growth Dynamics

The growth and adoption of canine cancer screening vary substantially across regions, influenced by infrastructure maturity and policy considerations. In North America, research funding and collaboration have driven the uptake of advanced screening platforms. Europe, facilitated by regulatory harmonization, exhibits a consistent testing standard, while Asia-Pacific shows rapid demand expansion due to advancements in veterinary healthcare, particularly in East Asia. These findings inform about global strategic opportunities and help guide resource allocation decisions.

Competitive Landscape and Strategic Collaborations

The canine cancer screening market is characterized by a dynamic competitive ecosystem, with strategic alliances playing a crucial role in innovation. Industry leaders are investing in next-generation sequencing and AI imaging solutions, collaborating with academic institutions to co-develop proprietary biomarker panels. Meanwhile, smaller firms focus on niche innovations, meeting specific diagnostic needs with modular kits that seamlessly integrate into workflows. Vertical integration and strategic collaborations enhance competitive differentiation, providing a pathway to solidify industry leadership.

Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of liquid biopsy tests for early detection of canine cancer using circulating tumor DNA
5.2. Integration of artificial intelligence algorithms in veterinary imaging for precise tumor screening and classification
5.3. Development of point-of-care handheld devices for noninvasive Raman spectroscopy-based cancer screening in dogs
5.4. Expansion of breed-specific genetic risk panels guiding personalized screening schedules for canine oncology
5.5. Growth of pet insurance reimbursement policies driving increased canine cancer screening and diagnostic testing
5.6. Collaboration between veterinary clinics and biotech firms to discover novel blood-based biomarkers for canine tumors
5.7. Remote telemedicine platforms facilitating virtual consultations and at-home canine cancer screening services
6. Market Insights
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025

8. Canine Cancer Screening Market, by Product Type
8.1. Introduction
8.2. Instruments
8.2.1. Imaging Instruments
8.2.2. Molecular Instruments
8.2.3. Sequencing Platforms
8.3. Reagents & Kits
8.3.1. Eliza Kits
8.3.2. NGS Kits
8.3.3. PCR Reagents
8.4. Services
8.4.1. Contract Research
8.4.2. Laboratory Services
9. Canine Cancer Screening Market, by Technology
9.1. Introduction
9.2. Biomarker Assays
9.2.1. Elisa
9.2.2. Immunohistochemistry
9.3. Genetic Testing
9.3.1. PCR Based
9.3.2. Sequencing Based
9.4. Imaging
9.4.1. CT
9.4.2. MRI
9.4.3. Ultrasound
9.4.4. X-Ray
9.5. Molecular Diagnostics
9.5.1. NGS
9.5.2. PCR
9.5.3. QPCR
10. Canine Cancer Screening Market, by End User
10.1. Introduction
10.2. Diagnostic Laboratories
10.2.1. Clinical Laboratories
10.2.2. Reference Laboratories
10.3. Research Institutes
10.3.1. Academic Institutions
10.3.2. Private Research
10.4. Veterinary Clinics
10.4.1. Small Animal Clinics
10.4.2. Specialty Clinics
10.5. Veterinary Hospitals
10.5.1. Corporate Hospitals
10.5.2. Independent Hospitals
11. Canine Cancer Screening Market, by Cancer Type
11.1. Introduction
11.2. Hemangiosarcoma
11.3. Lymphoma
11.4. Mammary Tumors
11.5. Skin Cancer
12. Canine Cancer Screening Market, by Sample Type
12.1. Introduction
12.2. Blood
12.3. Fine Needle Aspirate
12.4. Saliva
12.5. Tissue Biopsy
12.6. Urine
13. Americas Canine Cancer Screening Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Canine Cancer Screening Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Canine Cancer Screening Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
The companies profiled in this Canine Cancer Screening market report include:

• IDEXX Laboratories, Inc.
• Zoetis Inc.
• Heska Corporation
• Neogen Corporation
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Eurofins Scientific SE
• Danaher Corporation
• Virbac SA
• Covetrus, Inc.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08092025004107003653ID1110032052